Select publications
Green E et al. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Proc ASCO GI Symposium 2005;Abstract 182.
Labianca R et al. Alternating versus continuous “FOLFIRI” in advanced colorectal cancer (ACC): A randomized “GISCAD” trial. Proc ASCO 2006; Abstract 3505.
Maindrault-Goebel F et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2006;Abstract 3504.
Pasetto LM et al. Oxaliplatin-related neurotoxicity: How and why? Crit Rev Oncol Hematol 2006;59(2):159-68. Abstract
Saltz LB et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Proc ASCO GI Symposium 2007;Abstract 238.
Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR study. J Clin Oncol 2006;24(3):394-400. Abstract
